. 2022 Oct 16;29(10):7816–7831. doi: 10.3390/curroncol29100618

Table 2.

Published details of KIF5B-ALK-positive NSCLC patients treated with ALK-TKIs.

	Ref	Year	Variants	ALK-TKIs	Treatment	Response
1	Takeuchi, K. et al. [29]	2009	(K24:A19)	Not treated with ALK-TKIs	–	–
2	Wong, D.W. et al. [16]	2011	(K15:A20)	Not treated with ALK-TKIs	–	–
3	Zeng, H. et al. [78]	2021	(K20:A20)	Crizotinib Ceritinib	First line Second line	PFS: 11 m PFS > 9 m